On 1 February 2023, IPSF submitted a statement delivered on behalf of IPSF, IAPO, and IFPMA for the WHO EB152 agenda item related to substandard and falsified medical products.
Read moreIFPMA delivered a constituency statement for the agenda item related to strengthening the global architecture for health emergency preparedness, response, and resilience at the 152nd session of the Executive Board at the World Health Organization in Geneva.
Read moreFollowing on the heels of COVID-19, global rules on pandemic preparedness and response are being overhauled. Negotiations on a Global Pandemic Accord will kick off in February 2023, and the International Health Regulations (IHR) on responding to global public health emergencies are being revised. Against that background, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) requested that...
Read more
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the body representing the research-based pharmaceutical industry to the United Nations and the global stage, announced that Elliot Dunster will be joining the trade body on 17 April as Executive Director of Communications. He will be taking over the role from Abigail Jones, who is retiring in the course of 2023.
Read more
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreChildhood vaccination is recognized as one of the greatest medical success stories of the 20th century. Apart from clean water, no other intervention has had a bigger impact on global public health, especially for children, their families, and communities. In fact, vaccines have done such a good job of eradicating, eliminating or controlling certain infectious diseases that many of us have forgotten, or no longer worry, that our children or loved ones might still contract diseases like polio, measles or diphtheria.
Read more
IFPMA expresses its disappointment at the decision to consider an extension of a waiver of intellectual property rights on COVID-19 therapeutics and diagnostics taken by Member States at the World Trade Organization (WTO).
Read moreWe welcome the adoption at the 15th meeting of the Conference of the Parties to the UN Convention on Biological Diversity (COP15) of a framework that addresses biodiversity loss across the globe.
Read moreToday, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced Sunao Manabe, President and Chief Executive Officer (CEO) at Daiichi Sankyo, as IFPMA Vice President. IFPMA President and CEO of UCB, Jean-Christophe Tellier welcomes Sunao Manabe, President and CEO of Daiichi Sankyo to IFPMA leadership team. “I am thrilled Sunao will join IFPMA’s leadership team,”...
Read more
Immunization is the greatest success story of the twentieth century. Vaccines eliminated most of the childhood diseases that used to cause millions of deaths, making possible a life without disabilities caused by certain communicable diseases like polio for the first time in human history.
Read more
Ever since the smallpox vaccine discovery over two centuries ago, vaccines have successfully worked to eradicate, eliminate, or control many infectious diseases.
Read more
Ann-Lise Mikolajczak, Manager, Global Health and Access at IFPMA and Luca Deplano, Associate Manager, Innovation and Access Policy at IFPMA, joined Ryculture Health and Social Innovation’s 2nd Annual YouTH Voices Summit, focused on activating youthful leadership toward the realization of universal health coverage.
Read more